SciSparc

Company Overview

Snapshot

Founded in August 2004, SciSparc operates with 1–10 employees and has raised a total of $63.76 million across 12 funding rounds. The company went public on NASDAQ in March 2017, marking a significant milestone in its journey.

Business overview

SciSparc is a clinical-stage pharmaceutical company specializing in the development and enhancement of cannabinoid-based pharmaceuticals. The company's core technology focuses on drug development programs utilizing THC and/or non-psychoactive cannabidiol (CBD) for various central nervous system disorders. SciSparc serves the pharmaceutical and healthcare industries, with current programs targeting Tourette syndrome, obstructive sleep apnea, Alzheimer's disease and agitation, pain management, autism spectrum disorder, and epilepsy.

Strategic signal

In October 2025, SciSparc announced the closing of an acquisition of a publicly traded company on the TSXV, to which it transferred its advanced clinical-stage pharmaceutical portfolio. This strategic move indicates SciSparc's intent to consolidate its clinical assets and potentially expand its market presence through the acquired entity, signaling a significant shift in its operational structure and a focus on accelerating its drug development pipeline.

Company Intelligence Q&A

What was a key strategic move for SciSparc in October 2025?

In October 2025, SciSparc announced the closing of the acquisition of a publicly traded company on the TSXV. This acquisition involved the transfer of SciSparc's advanced clinical-stage pharmaceutical portfolio to the acquired entity.

What was the outcome of the N2OFF merger in September 2025?

In September 2025, N2OFF shareholders approved the merger with SciSparc’s majority-owned subsidiary, MitoCareX, a drug discovery company focused on resistant cancers including pancreatic and non-small cell lung cancer.

What new initiative did SciSparc resolve to launch in September 2025?

In September 2025, SciSparc resolved to launch an innovative quantum computing-enabled 3D protein modeling initiative. This initiative aims to revolutionize AI drug discovery.

What regulatory approval did SciSparc receive in September 2024?

In September 2024, SciSparc secured FDA green light to launch its pivotal Phase IIb clinical trial in the US for a breakthrough Tourette Syndrome treatment.

What was a significant development in SciSparc's collaboration with Clearmind Medicine in September 2024?

In September 2024, the collaboration between SciSparc and Clearmind Medicine led to the publication of an international patent application for an innovative MDMA-based combination treatment.